Age-Related Macular Degeneration Market Size, Share, Growth and Forecast (2026 - 2036)

Age-Related Macular Degeneration Market Size, Market Forecast and Outlook by Fact.MR

• The age-related macular degeneration market was valued at USD 13.1 billion in 2025.
• Demand is set to reach USD 13.9 billion in 2026. The market is projected to record 6.8% CAGR from 2026 to 2036.
• Wider anti-VEGF use and geographic atrophy treatment adoption are forecast to lift the market to USD 26.9 billion by 2036.

Summary of Age-Related Macular Degeneration Market

• Demand Drivers in the Market
  • Aging Population: AMD risk increases with age. Older patient groups create steady demand for retinal screening and follow-up care.
  • Wet AMD Treatment: Wet AMD can damage vision quickly. Anti-VEGF injections remain the main treatment used to slow vision loss.
  • Geographic Atrophy Therapy: Dry AMD care now includes approved geographic atrophy treatments. This creates a new drug demand route for patients with advanced dry AMD care.
• Key Segments Analyzed
  • By Disease Type: Wet AMD is projected to record 64.0% share in 2026 as active injection therapy creates recurring treatment demand.
  • By Product: Eylea & Eylea HD lead because aflibercept remains widely used in retinal care. The product group is estimated to hold 35.0% share in 2026.
  • By Drug Class: Anti-VEGF therapy is projected to account for 76.0% share in 2026 because wet AMD treatment depends on vascular growth control.
  • By Distribution Channel: Hospital pharmacy leads because injectable retinal therapies need controlled handling and specialist administration. The channel is expected to hold 51.0% share in 2026.
  • By End User: Ophthalmology clinics are projected to account for 47.0% share in 2026 because retinal specialists manage repeated AMD injections.
  • By Geography: United States AMD treatment demand is forecast to grow at 6.7% CAGR from 2026 to 2036 as anti-VEGF use and geographic atrophy therapy adoption continue.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Senior Analyst at Fact.MR, states, “AMD treatment demand is becoming more therapy-specific. Retina specialists need durable response and practical dosing. Companies that combine clinical evidence with patient access support can protect repeat use.”
• Strategic Implications
  • Dosing Burden: Drug makers must reduce visit pressure. Longer treatment intervals can improve patient adherence.
  • Access Support: Clinics need clear insurance approval and patient support. Delays can stop patients from getting treatment on time.
  • Evidence Quality: New therapies need clear vision and safety data. Retina specialists adopt them faster when the data is useful in daily practice.

AMD treatment demand is increasing because the condition damages central vision. This can affect daily tasks such as reading and driving. Wet AMD needs active treatment to slow vision loss. Dry AMD creates a wider patient group. Geographic atrophy is creating demand for new treatment options in advanced dry AMD care.

Retinal care is moving toward longer-acting therapies that can reduce treatment burden. Clinics need drugs that match follow-up schedules. Patients also need earlier diagnosis and better access to treatment. Payers need clear proof that these therapies help protect vision.

China is forecast to grow at 6.5% CAGR from 2026 to 2036 as hospital retinal care access improves and diagnosed AMD volumes rise. The United States market is set to rise at 6.7% CAGR through 2036 as established anti-VEGF use supports repeat treatment demand. The United Kingdom records 6.3% CAGR over the study period as retinal services and follow-up care support steady treatment use. India is projected to grow at 6.1% CAGR from 2026 to 2036 because hospital access and older patient screening are improving. South Korea may record 5.7% CAGR through 2036 as specialist eye care expands. Germany follows at 5.6% CAGR in the assessment period through mature ophthalmology care and treatment access. Japan is forecast to grow at 5.4% CAGR through 2036 as aging-linked retinal treatment demand increases.

Segmental Analysis

Age-Related Macular Degeneration Market Analysis by Disease Type

Wet AMD is projected to record 64.0% share in 2026 because active injection therapy creates recurring treatment demand. Dry AMD has a wider patient group with lower treatment intensity. BrightFocus Foundation states that most people with wet AMD need eye injections every four to 12 weeks, and dry AMD treatment activity is gaining attention through geographic atrophy therapies. [1] Wet AMD leads because patients need repeated specialist care.

• Wet AMD: Wet AMD needs active treatment and follow-up. Anti-VEGF injections help slow vision loss.
• Dry AMD: Dry AMD creates broad monitoring demand. Treatment value rises when disease advances.
• Geographic Atrophy: Geographic atrophy treatment is growing after new drug approvals. This gives advanced dry AMD patients a therapy route.

Age-Related Macular Degeneration Market Analysis by Product

Eylea and Eylea HD lead because aflibercept is widely used in wet AMD treatment. Vabysmo adds demand through dual-pathway action and flexible dosing. Eylea and Eylea HD are estimated to hold 35.0% share in 2026 as retinal specialists continue to use aflibercept for repeat treatment. Their lead is tied to established clinical use and dosing flexibility in retinal care.

• Eylea Base: Eylea supports routine wet AMD care. Eylea HD adds longer-interval treatment potential.
• Vabysmo Use: Vabysmo targets VEGF-A and Ang-2. This gives physicians another option for retinal disease control.
• GA Products: Syfovre supports geographic atrophy treatment. It expands therapy beyond wet AMD.

Age-Related Macular Degeneration Market Analysis by Drug Class

Anti-VEGF therapy is projected to account for 76.0% share in 2026 because wet AMD treatment depends on vascular growth control. Complement inhibitors serve geographic atrophy patients. A 2025 review states that intravitreal anti-VEGF therapy is the current gold-standard treatment for neovascular AMD. [2] Other drug classes are smaller because most active AMD treatment still depends on eye injections. Anti-VEGF therapy leads the market because it is the main treatment used for neovascular AMD.

• Anti-VEGF Therapy: Anti-VEGF drugs reduce bleeding and leakage. Retina specialists use them as core wet AMD treatment.
• Complement Inhibitors: Complement inhibitors support geographic atrophy care. These drugs add treatment demand in dry AMD.
• Other Classes: Other approaches remain selective. Commercial uptake depends on proof and access.

Age-Related Macular Degeneration Market Analysis by Distribution Channel

Hospital pharmacies lead because retinal injections need proper storage and are usually given in specialist care centers. Specialty pharmacies help patients get access to these medicines and support insurance approval. Hospital pharmacies are expected to hold 51.0% share in 2026 as AMD drugs remain tied to specialist treatment sites. Their lead is linked to cold-chain handling and clinical injection workflows.

• Hospital Pharmacy: Hospital pharmacies support controlled drug handling. They serve patients treated in specialist settings.
• Specialty Pharmacy: Specialty pharmacies help with access and reimbursement. They support therapies that require benefit review.
• Retail Pharmacy: Retail pharmacy use remains limited. AMD injections are not routine self-administered products.

Age-Related Macular Degeneration Market Analysis by End User

Ophthalmology clinics are projected to account for 47.0% share in 2026 because retinal specialists manage repeat AMD injections and follow-up routines. Hospitals manage serious AMD cases and help patients get the medicines they need. Ambulatory surgical handle selected eye procedures. Ophthalmology clinics lead because patients need regular checkups and treatment from retina specialists.

• Ophthalmology Clinics: Clinics handle repeated AMD injections and monitoring. Retina specialists guide treatment intervals.
• Hospitals: Hospitals support complex retinal care. They help manage higher-risk patients and pharmacy access.
• Ambulatory Centers: Ambulatory centers support selected procedures. Their role depends on local care models.

Age-Related Macular Degeneration Market Drivers, Restraints, and Opportunities

Aging and retinal disease burden are the main growth drivers. Wet AMD therapy creates repeat treatment demand because patients need regular injections and eye checkups. New treatments for geographic atrophy are also increasing demand in advanced dry AMD care. Specialist follow-up supports sustained market value through regular diagnosis and treatment scheduling.

Treatment burden is the main restraint. Many patients need repeated injections, which can be difficult for both patients and eye clinics. High treatment cost can also affect access. Long-term retinal care needs safety monitoring and clear evidence of vision benefit.

Opportunities in the Age-Related Macular Degeneration Market

• Longer-Interval Therapy: Retinal therapy developers are working to reduce frequent clinic visits through longer dosing intervals. Approved longer-acting options support this shift in wet AMD care.
• Geographic Atrophy Care: Complement inhibitor use is expanding treatment options for advanced dry AMD. Approved therapies give clinics a clearer route to treat geographic atrophy.
• Specialist Access: Ophthalmology clinics support patient follow-up and retinal monitoring. Anti-VEGF guidance reinforces the need for specialist-led wet AMD care.

Regional Analysis

Based on regional analysis, the age-related macular degeneration market is segmented into North America, Latin America, Europe, East Asia, South Asia and Oceania, and Middle East and Africa.

Country CAGR (2026 to 2036)

Source: Fact.MR analysis based on adjusted forecast model and primary research.

North America Age-Related Macular Degeneration Market Analysis

North America demand is growing because patients have access to retina specialists and approved AMD drugs. The United States leads through established anti-VEGF use. Geographic atrophy therapy adds another treatment route.

• United States: United States AMD treatment demand is forecast to grow at 6.7% CAGR from 2026 to 2036. Growth is supported by regular anti-VEGF treatment for wet AMD and rising use of geographic atrophy therapies. The American Academy of Ophthalmology states that wet AMD is treated with periodic eye injections, and newer treatment options are expanding dry AMD care. [3] FDA-approved retinal drugs also support continued treatment through retina specialists .

East Asia Age-Related Macular Degeneration Market Analysis

East Asia demand is growing because more older patients need retinal care. China is improving hospital-based diagnosis and treatment access. Japan and South Korea support demand through specialist eye care services.

• China: AMD treatment demand in China is forecast to grow at 6.5% CAGR over the study period. Growth is supported by better hospital access and earlier retinal diagnosis. Older patients are also entering regular follow-up care. Patient awareness remains important because early diagnosis helps patients stay on treatment.
• South Korea: South Korea is anticipated to record 5.7% CAGR by 2036 as specialist eye care expands. A 2025 BMC Ophthalmology study states that anti-VEGF injections are standard treatment for exudative AMD and that ranibizumab and aflibercept have been widely used in South Korea after health insurance coverage expanded. [4] South Korea grows through specialist care and therapy access.
• Japan: Japan AMD treatment demand is supported by established eye care access and aging-linked retinal disease demand. Japan is forecast to grow at 5.4% CAGR through 2036 as older patients need retinal monitoring and treatment. Aging increases demand for wet AMD therapy and advanced dry AMD care. Ophthalmology clinics need drugs with clear safety data and practical dosing schedules.

South Asia and Oceania Age-Related Macular Degeneration Market Analysis

South Asia and Oceania demand is growing as hospitals improve eye care and screening. India is the main growth market in the region. Private hospitals are adding retinal services, which is making treatment easier to access.

• India: India is projected to grow at 6.1% CAGR from 2026 to 2036 as hospital-based retinal care and screening improve. Retina specialists need anti-VEGF products that patients can afford in repeated treatment cycles. Early diagnosis can also help patients start treatment before vision loss become more serious.

Europe Age-Related Macular Degeneration Market Analysis

Europe demand is growing because older patients need regular retinal care. The region has well-established ophthalmology services and access to approved AMD treatments. The United Kingdom benefits from specialist retinal care pathways. Germany gains from clinic access and planned follow-up care.

• United Kingdom: United Kingdom AMD treatment demand is forecast to record 6.3% CAGR from 2026 to 2036. Retina clinics need treatments that reduce visit pressure and maintain outcomes. Royal Devon University Healthcare NHS Foundation Trust states that most anti-VEGF patients begin with three injections spaced four weeks apart, with later treatment guided by leakage and regular monitoring. [5] Geographic atrophy care creates a separate pathway for advanced dry AMD. The United Kingdom grows through specialist care and therapy access.
• Germany: Germany AMD treatment demand is supported by retinal specialist care and scheduled follow-up. Germany is forecast to grow at 5.6% CAGR through 2036 as ophthalmology clinics use wet AMD injections and geographic atrophy therapies. Approved drug access helps patients continue treatment over time.

Competitive Aligners for Market Players

The age-related macular degeneration market includes retinal drug companies and ophthalmology therapy developers. Regeneron competes through Eylea and Eylea HD. Roche competes through Vabysmo and Lucentis. Bayer supports Eylea commercialization in several markets. Novartis competes through Beovu. Apellis competes through Syfovre for geographic atrophy.

Competition in the AMD treatment market depends on how well a drug works and how easy it is for patients to access it. Wet AMD drugs with longer dosing intervals are helping reduce the number of clinic visits. New geographic atrophy treatments are also expanding care options for advanced dry AMD. This shows that companies are competing on fewer visits and wider treatment coverage.

Company growth will depend on clinical results through 2036. Retina specialists need treatments that match regular patient follow-up schedules. Payers need clear proof that the drugs help protect vision. Clinics also need reliable drug supply and access support. Companies with effective treatments and practical dosing schedules can keep steady demand.

Key Players

• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Bayer AG
• Novartis AG

Bibliography

• [1] BrightFocus Foundation. (2025, July 25). Emerging treatments offer new hope for dry and wet age-related macular degeneration.
• [2] Stoica, A. M., et al. (2025). Anti-VEGF therapy: A new hope in AMD treatment. International Journal of Molecular Sciences.
• [3] American Academy of Ophthalmology. (2026, January 5). New treatments for age-related macular degeneration.
• [4] Cho, Y., Yoo, W.-S., Kim, S.-J., & Chung, I. (2025, October 24). Characteristics of patients lost to follow-up after intravitreal anti-vascular endothelial growth factor therapy for exudative age-related macular degeneration.
• [5] Royal Devon University Healthcare NHS Foundation Trust. (2025, October). Anti-VEGF intravitreal injection treatment.

This Report Addresses

• Strategic intelligence on AMD treatment demand across wet AMD and dry AMD.
• Growth opportunity mapping across the United States and China plus the United Kingdom and India.
• Segment analysis by disease type, product, drug class, distribution channel, and end user.
• Regional outlook covering retinal specialist access, anti-VEGF use, geographic atrophy therapy, and patient follow-up needs.
• Competitive analysis of Regeneron Pharmaceuticals, Roche, Bayer, Novartis, and Apellis Pharmaceuticals.
• Product assessment covering Eylea & Eylea HD, Vabysmo, Lucentis, Beovu, and Syfovre.
• Report delivered through PDF, Excel datasets, and presentation formats.
• Primary interviews, supplier checks, and AMD treatment demand review support validation.

Age-Related Macular Degeneration Market Definition

The age-related macular degeneration market covers therapies used to manage retinal damage linked to aging. It includes wet AMD treatments and dry AMD therapies. It includes geographic atrophy drugs. The market differs from general eye care because treatment targets macular damage and vision loss risk.

Age-Related Macular Degeneration Market Inclusions

The scope includes anti-VEGF injections and complement inhibitors. It includes branded AMD drugs used in specialist care. Hospital pharmacy and specialty pharmacy sales are covered. Ophthalmology clinics are counted when they administer AMD therapy.

Age-Related Macular Degeneration Market Exclusions

The scope excludes routine eye exams and vision correction products. General eye drops are outside scope unless used for AMD treatment. Diagnostic equipment is excluded. Nutritional supplements are excluded unless sold as regulated AMD therapy.

Age-Related Macular Degeneration Market Research Methodology

• Primary Research
  • Primary research includes interviews with retina specialists and ophthalmology clinic managers. Hospital pharmacy staff were reviewed for drug access patterns. Specialty pharmacy operators were reviewed for patient support needs. Supplier checks supported product and channel assumptions.
• Desk Research
  • Desk research reviewed AMD treatment guidance and drug approval pages. Company product releases supported active therapy validation. Public health pages supported disease burden logic. Regulatory sources supported product access review.
• Market-Sizing and Forecasting
  • Forecasting uses disease type demand and product adoption. Drug class demand is linked to wet AMD therapy and geographic atrophy treatment. Distribution estimates reflect hospital and specialty pharmacy use.
• Data Validation and Update Cycle
  • Forecasts are validated through specialist checks. Pharmacy feedback supports channel review. Regional assumptions are reviewed with treatment access and aging-related retinal care trends.